NCT03374852View on ClinicalTrials.gov

CPI-613 in Combination With Modified FOLFIRINOX in Patients With Locally Advanced Pancreatic Cancer

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

August 31, 2018

Primary Completion Date

October 5, 2019

Study Completion Date

October 31, 2020

Conditions
Pancreatic Ductal Adenocarcinoma
Interventions
DRUG

CPI-613

500 mg/m2, IV infusion at a rate of 4 mL/min via a central venous port

DRUG

mFOLFIRNOX

mFOLFIRNOX (given immediately after CPI-613 administration):

Sponsors
All Listed Sponsors
collaborator

Cornerstone Pharmaceuticals

INDUSTRY

lead

Sidney Kimmel Cancer Center at Thomas Jefferson University

OTHER

NCT03374852 - CPI-613 in Combination With Modified FOLFIRINOX in Patients With Locally Advanced Pancreatic Cancer | Biotech Hunter | Biotech Hunter